| Literature DB >> 29216328 |
Lengmei Cheng1, Wei Yan2, Liping Zhu1,2, Yiying Chen2, Jie Liu2, Yan Xu2, Lu Ji2, Junrong He3.
Abstract
BACKGROUND: Currently, the prevalence of metabolic syndrome (MS) has attracted widespread public attention. However, there is a war regarding the applicability of the diagnosis in different populations regarding the distinct criteria for the diagnosis of MS. Data about the prevalence rate of MS and its components in Jiangxi Province are limited. Thus, our goals were to compare the consistency rates and applicability of three criteria, i.e., those of the International Diabetes Federation (IDF), the National Cholesterol Education Program Adult Treatment PanelⅢ (ATPⅢ), and the Chinese Diabetes Society (CDS).Entities:
Mesh:
Year: 2017 PMID: 29216328 PMCID: PMC5720703 DOI: 10.1371/journal.pone.0189046
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
The three criteria for MS.
| Components | IDF (2005) | ATPⅢ(2005) | CDS (2004) |
|---|---|---|---|
| Obesity (Chinese) | waist circumference (WC)≥90cm (male) or ≥80 cm (female) | 1.waist circumference (WC)≥90 cm (male) or ≥80 cm (female) | 1.BMI≥25.0 kg/m2 |
| Elevated blood pressure | 1.systolic blood pressure (SBP)≥130 or diastolic blood pressure (DBP) ≥85 mmHg or treatment of previously diagnosed hypertension | 2.systolic blood pressure (SBP)≥130 or diastolic blood pressure (DBP)≥85 mmHg or on antihypertensive drug treatment in a patient with a history of hypertension | 2.systolic blood pressure (SBP)≥140ordiastolic blood pressure (DBP)≥90mmHg and (or) treatment of previously diagnosed hypertension |
| Hyperglycemia | 2.fasting plasma glucose (FPG) ≥ 100 mg/dL (5.6) mmol/L), or previously diagnosed type 2 diabetes | 3.fasting plasma glucose (FPG)≥100 mg/dL (5.6mmol/L) or on drug treatment for elevated glucose | 3.fasting plasma glucose (FPG)≥110 mg/dL (6.1 mmol/L) and (or) 2 hours postprandial plasma glucose (2hPPG)≥140 mg/dL (7.8 mmol/L), and (or) on drug treatment for diabetes |
| Dyslipidemia | 3.triglyceride (TG)≥ 150 mg/dL (1.7 mmol/L) orspecific treatment for this lipid abnormality at high-density4.high density lipoprotein cholesterol (HDL-C)< 40 mg/dL (1.03 mmol/L) (male),<50 mg/dL (1.29 mmol/L)(female)or specific treatment for this lipid abnormality | 4.triglyceride (TG)≥ 150 mg/dL (1.7 mmol/L) or on drug treatment for elevated triglycerides 5.high density lipoprotein cholesterol (HDL-C)< 40 mg/dL (1.03 mmol/L) (male),<50 mg/dL (1.3 mmol/L) (female)or on drug treatment for reduced HDL | 4.triglyceride(TG)≥ 150 mg/dL (1.7 mmol/L) and (or) high density lipoprotein cholesterol (HDL-C)< 35 mg/dL (0.9 mmol/L) (male)< 39 mg/dL (1.0 mmol/L) (female) |
Note: MS was diagnosed as follows: the IDF criterion: a person with abdominal obesity (waist circumference≥90 cm (male) or ≥80 cm (female), plus any two risk factors labeled 1~4; the ATPⅢ criterion: a person with at least three of the factors labeled 1~5; and the CDS criterion: a person with at least three of the factors labeled 1~4.
Characteristics of the participants.
| Variables | Total | Male | Female | |
|---|---|---|---|---|
| N | 5959 | 2451 | 3508 | — |
| Age (years) | 50.52±13.92 | 51.23±14.47 | 50.03±13.50 | 0.01 |
| Height(cm) | 157.42±8.12 | 163.44±6.82 | 153.22±6.04 | <0.01 |
| Weight(kg) | 57.95±10.48 | 62.56±10.89 | 54.74±8.86 | <0.01 |
| WC (cm) | 80.80±9.33 | 82.73±9.52 | 79.46±8.96 | <0.01 |
| BMI (kg/m2) | 23.31±3.32 | 23.34±3.33 | 23.28±3.31 | 0.48 |
| SBP (mmHg) | 127.42±20.09 | 129.65±18.78 | 125.87±20.81 | <0.01 |
| DBP (mmHg) | 75.42±11.12 | 77.61±11.43 | 73.88±10.63 | <0.01 |
| FPG (mmol/L) | 5.52±1.33 | 5.56±1.32 | 5.49±1.34 | 0.05 |
| 2hPPG (mmol/L) | 6.22±2.35 | 6.18±2.53 | 6.25±2.22 | 0.32 |
| HDL-C (mmol/L) | 1.37±0.38 | 1.33±0.40 | 1.40±0.36 | <0.01 |
| LDL-C(mmol/L) | 2.86±0.83 | 2.85±0.82 | 2.87±0.83 | 0.33 |
| CHOL(mmol/L) | 4.66±0.93 | 4.65±0.92 | 4.67±0.94 | 0.42 |
| TG (mmol/L) | 1.40±1.16 | 1.49±1.36 | 1.33±0.99 | <0.01 |
* Compared between male and female
The data are presented as the means ± the SDs.
WC, waist circumference; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; 2hPPG, 2-hour postprandial plasma glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; CHOL, cholesterol; TG, triglycerides.
The prevalent rates of the components of MS by gender (according to the IDF, ATPⅢ, and CDS criteria).
| Diagnostic criteria | Total | Male | Female | χ2 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Prevalence | Prevalence rate | Prevalence | Prevalence | Prevalence | Prevalence | ||||
| Overweight or obese | CDS | 1685 | 28.28% | 747 | 30.48% | 938 | 26.74% | 9.89 | <0.01 |
| Central obesity | IDF/ ATPⅢ | 2249 | 37.74% | 609 | 24.85% | 1640 | 46.75% | 294.01 | <0.01 |
| Hypertriglyceridemia | IDF/ ATPⅢ | 1432 | 24.03% | 655 | 26.72% | 777 | 22.15% | 16.48 | <0.01 |
| Reduced HDL-C | IDF | 2071 | 34.75% | 618 | 25.21% | 1453 | 41.42% | 167.62 | <0.01 |
| ATPⅢ | 2117 | 35.53% | 618 | 25.21% | 1499 | 42.73% | 193.88 | <0.01 | |
| Elevated blood pressure | IDF/ ATPⅢ | 2483 | 41.67% | 1154 | 47.08% | 1329 | 37.88% | 51.26 | <0.01 |
| CDS | 1656 | 27.79% | 744 | 30.35% | 912 | 26.00% | 14.01 | <0.01 | |
| Hyperglycemia | IDF | 1918 | 32.19% | 834 | 34.03% | 1084 | 30.90% | 6.31 | 0.01 |
| ATPⅢ | 1912 | 32.09% | 833 | 33.99% | 1079 | 30.76% | 6.74 | 0.01 | |
| CDS | 1346 | 22.59% | 591 | 24.11% | 755 | 21.52% | 5.73 | 0.02 | |
| Dyslipidemia | CDS | 1524 | 25.57% | 670 | 27.34% | 854 | 24.34% | 6.74 | 0.01 |
| MS | IDF | 1327 | 22.27% | 412 | 16.81% | 915 | 26.08% | 71.69 | <0.01 |
| ATPⅢ | 1670 | 28.02% | 594 | 24.24% | 1076 | 30.67% | 29.65 | <0.01 | |
| CDS | 698 | 11.71% | 320 | 13.06% | 378 | 10.78% | 7.26 | 0.01 | |
| MS | IDF | — | 19.85% | — | 16.98% | — | 22.11% | — | — |
| ATPⅢ | — | 24.77% | — | 23.86% | — | 25.76% | — | — | |
| CDS | — | 9.95% | — | 12.31% | — | 8.50% | — | — | |
* Compared between the male and female.
** Standardized prevalence rate of MS.
Analysis on validity of different criteria for MS.
| Test criteria | Reference criteria | Total | Male | Female | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Sensitivity (%) | Specificity (%) | Youden’s index | Sensitivity (%) | Specificity (%) | Youden’s index | Sensitivity (%) | Specificity (%) | Youden’s index | ||
| IDF | ATPⅢ | 79.40 | 99.98 | 0.79 | 69.36 | 100 | 0.69 | 85.94 | 99.96 | 0.86 |
| CDS | ATPⅢ | 38.86 | 98.86 | 0.38 | 48.48 | 98.28 | 0.47 | 33.55 | 99.30 | 0.33 |
Consistencies in the diagnoses of MS according to the three criteria.
| Indexes | Total | Male | Female | |||
|---|---|---|---|---|---|---|
| N | Consistency rate (%) | N | Consistency rate (%) | N | Consistency rate (%) | |
| IDF(+)ATPⅢ (+) / IDF(-)ATPⅢ (-) | 5614 | 94.21 | 2269 | 92.57 | 3345 | 95.35 |
| IDF(+)ATPⅢ (-) | 1 | 0 | 1 | |||
| IDF(-)ATPⅢ(+) | 344 | 182 | 162 | |||
| Kappa value | 0.85 | 0.77 | 0.89 | |||
| IDF(+) CDS(+) / IDF(-) CDS(-) | 5036 | 84.51 | 2169 | 88.49 | 2867 | 81.73 |
| IDF(+) CDS(-) | 776 | 187 | 589 | |||
| IDF(-) CDS(+) | 147 | 95 | 52 | |||
| Kappa value | 0.46 | 0.55 | 0.42 | |||
| ATPⅢ (+)CDS(+) / ATPⅢ (-) CDS(-) | 4889 | 82.04 | 2113 | 86.21 | 2776 | 79.13 |
| ATPⅢ (+) CDS(-) | 1021 | 306 | 715 | |||
| ATPⅢ (-) CDS(+) | 49 | 32 | 17 | |||
| Kappa value | 0.46 | 0.56 | 0.40 | |||
*P<0.05
Clustering of risk factors for MS predicted by cut-off point of WC and BMI.
| Cut-off point | Male | Female | |||||
|---|---|---|---|---|---|---|---|
| Sensitivity (%) | Specificity (%) | Distance of ROC | Sensitivity (%) | Specificity (%) | Distance of ROC | ||
| BMI | 20kg/m2 | 99.0 | 21.3 | 0.79 | 97.1 | 20.2 | 0.80 |
| 21kg/m2 | 96.8 | 33.8 | 0.66 | 94.5 | 33.4 | 0.67 | |
| 22kg/m2 | 93.3 | 48.3 | 0.52 | 88.5 | 48.6 | 0.53 | |
| 23kg/m2 | 88.6 | 61.2 | 0.40 | 78.6 | 62.7 | 0.43 | |
| 81.8 | 72.7 | 0.33 | 66.1 | 74.9 | 0.42 | ||
| 25kg/m2 | 69.4 | 81.9 | 0.36 | 52.3 | 84.4 | 0.50 | |
| 26kg/m2 | 55.2 | 89.1 | 0.46 | 38.5 | 89.6 | 0.62 | |
| 27kg/m2 | 39.7 | 93.1 | 0.61 | 25.7 | 93.2 | 0.75 | |
| 28kg/m2 | 24.4 | 96.8 | 0.76 | 17.5 | 95.6 | 0.83 | |
| WC | 77cm | 96.3 | 38.1 | 0.62 | 90.9 | 56.0 | 0.45 |
| 78cm | 95.1 | 43.2 | 0.57 | 88.4 | 61.6 | 0.40 | |
| 79cm | 93.9 | 48.5 | 0.52 | 86.5 | 67.4 | 0.35 | |
| 92.8 | 53.7 | 0.47 | 80.9 | 72.5 | 0.33 | ||
| 81cm | 90.7 | 58.0 | 0.43 | 75.1 | 76.1 | 0.34 | |
| 82cm | 88.9 | 62.7 | 0.39 | 69.7 | 79.3 | 0.37 | |
| 83cm | 87.2 | 67.3 | 0.35 | 63.5 | 82.5 | 0.40 | |
| 84cm | 85.0 | 71.4 | 0.32 | 58.4 | 84.8 | 0.44 | |
| 85cm | 82.5 | 75.3 | 0.30 | 51.7 | 87.2 | 0.50 | |
| 86cm | 80.0 | 79.5 | 0.29 | 45.7 | 89.2 | 0.55 | |
| 77.4 | 82.7 | 0.28 | 41.3 | 91.2 | 0.59 | ||
| 88cm | 74.4 | 85.7 | 0.29 | 36.6 | 92.5 | 0.64 | |
| 89cm | 70.9 | 88.3 | 0.31 | 31.4 | 93.7 | 0.69 | |
| 90cm | 62.3 | 90.8 | 0.39 | 27.2 | 94.8 | 0.73 | |
| 91cm | 55.4 | 92.4 | 0.45 | 24.3 | 95.7 | 0.76 | |
| 92cm | 48.1 | 94.0 | 0.52 | 20.5 | 96.8 | 0.80 | |
At least three of the risk factors aggregation refer to ATPⅢ(2005) criterion.
# The optimal cut-off point of BMI for male and female.
* The optimal cut-off point of WC for male.
** The optimal cut-off point of WC for female.
The clusters of risk factors for MS predicted by cut-off point of WC and BMI in different age groups.
| Age group | Male | Female | |||||
|---|---|---|---|---|---|---|---|
| Sensitivity (%) | Specificity (%) | Distance of ROC | Sensitivity (%) | Specificity (%) | Distance of ROC | ||
| BMI≥25kg/m2 | 18~44 | 78.8 | 78.5 | 0.30 | 65.0 | 85.7 | 0.38 |
| 45~59 | 66.4 | 79.4 | 0.39 | 54.7 | 81.9 | 0.49 | |
| 60~ | 61.8 | 88.9 | 0.40 | 40.8 | 87.1 | 0.61 | |
| WC≥90/80cm | 18~44 | 68.5 | 89.3 | 0.33 | 86.5 | 76.5 | 0.27 |
| 45~59 | 58.1 | 89.6 | 0.43 | 79.9 | 69.3 | 0.37 | |
| 60~ | 61.8 | 94.0 | 0.39 | 79.2 | 70.6 | 0.36 | |
At least three of the risk factors clusters refer to ATPⅢ(2005) criterion.